Dr. Ariane Tom is the Founder & Managing Director of Kaleida Capital, a venture capital firm investing in neurotechnology and the future of computation. Under her management, Kaleida has achieved significant early successes. The firm’s first neurotech investment, Manifest Technologies, achieved an exit within just 16 months, delivering returns and establishing Kaleida’s credibility in this emerging field. Kaleida also backed Anthropic, a leader in AI innovation, which is rapidly scaling and driving transformative advances in the sector.

Ariane has applied over a decade of research insights to venture capital, patent law, and public policy, building a top-performing investment track record by identifying and backing transformative technology companies, including those developed by multiple Nobel Laureates. She has served on the Boards of companies spanning computationally-intensive applications such as neuroimaging, cancer diagnostics, drug discovery, and immunotherapy, and is an early thought leader in NeuroAI.

Throughout her academic career at Stanford, Ariane spearheaded groundbreaking research programs in neural interfaces with applications in brain-mapping, prosthetics, drug delivery, and neuromodulation. She is a published co-author in top-tier journals including Science and Nature Portfolio, collaborating with luminaries such as Karl Deisseroth (optogenetics & CLARITY), Zhenan Bao (electronic skin), and Sergiu Pasca (organoids).

As a sought-after thought leader in neurotechnology innovation, Ariane frequently speaks at global events to discuss advancements in neurotechnology and the evolving investment landscape. She holds a B.S. in Materials Science & Engineering, an M.S. in Bioengineering, and a Ph.D. in Bioengineering, all from Stanford University.